Story thread · 2 reports / 2 sources
Merck’s remigromig meets primary endpoint in diabetic macular edema trial
investing.com · 3h · first report
The coverage
- Merck’s diabetic macular edema therapy succeeds in Phase 2b/3 trial
seekingalpha.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.